Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval
Company expands injectable portfolio with therapeutically equivalent version of Vimpat®, targeting a market valued at approximately $15.2 million annually
Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe
Anbalagan has led end-to-end product development programs from concept to commercialization, with a strong focus on regulatory compliance, process scalability, and manufacturing readiness
Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio
The ventilator features a high-performance turbine capable of delivering up to 240 L/min peak flow
Dr. Rishi brings more than 15 years of experience in bioprocess development, microbial fermentation, technology transfer, and biotechnology operations
The industry is expected to grow significantly over the next few years as healthcare accessibility improves and insurance penetration increases
Regulatory clearance strengthens company’s global footprint and expands access to the Australian animal healthcare market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
